FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Farhad Ravandi

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Living Beings

Young Adult

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Koichi Takahashi; Michael Andreeff; Gautam Borthakur; Marylou Cardenas-Turanzas; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Hagop Kantarjian; Rajyalakshmi Luthra; Naveen Pemmaraju; Sherry Pierce; Farhad Ravandi; Jorge Cortes
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
Hagop Kantarjian; Farhad Ravandi; Wyndham Wilson; Elihu Estey
Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
Aref Al-Kali; Gautam Borthakur; Carlos E Bueso-Ramos; Jorges Cortes; Zeev Estrov; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Ayalew Tefferi; Guillermo Garcia-Manero
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Farhad Ravandi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Koichi Takahashi; Michael Andreeff; Gautam Borthakur; Marylou Cardenas-Turanzas; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Hagop Kantarjian; Rajyalakshmi Luthra; Naveen Pemmaraju; Sherry Pierce; Farhad Ravandi; Jorge Cortes
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
British journal of haematology 2013;161(5):659-66.
2013: Hagop Kantarjian; Farhad Ravandi; Wyndham Wilson; Elihu Estey
Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(14):1795-6.
2013: Aref Al-Kali; Gautam Borthakur; Carlos E Bueso-Ramos; Jorges Cortes; Zeev Estrov; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Ayalew Tefferi; Guillermo Garcia-Manero
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
American journal of hematology 2013;88(5):365-9.
2013: Michael S Mathisen; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Alfonso Quintás-Cardama
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Clinical lymphoma, myeloma & leukemia 2013;13(2):139-43.
2013: Vijaya Raj Bhatt; Jorge E Cortes; Hagop Kantarjian; Farhad Ravandi; Gautam Borthakur
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results.
Clinical lymphoma, myeloma & leukemia 2013;13(2):153-8.
2013: Elias Jabbour; Susan O'Brien; Farhad Ravandi; William Wierda; Jorge E Cortes; Stefan Faderl; Amber Fullmer; Guillermo Garcia-Manero; Hagop Kantarjian
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Clinical lymphoma, myeloma & leukemia 2013;13(2):131-8.
2013: Y Chen; Jorge Cortes; N Daver; Marcos De Lima; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; T Kadia; Andrew Lamb; Partow Kebriaei; Susan O'Brien; Sherry Pierce; W Qiao; Lynne V Abruzzo; Farhad Ravandi
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.
Leukemia 2013;27(4):836-42.
2013: Roland B Walter; Frederick R Appelbaum; Alan K Burnett; Anna Evans; Robert K Hills; Hagop M Kantarjian; Bob Löwenberg; Gert J Ossenkoppele; Megan Othus; Sherry R Pierce; Farhad Ravandi; Kees G M van Montfort; Elihu H Estey
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Blood 2013;121(13):2424-31.
2013: Betul Oran; Uday Popat; Muzaffar H Qazilbash; Farhad Ravandi; Gabriela Rondon; Lynn Abruzzo; Borje S Andersson; Qaiser Bashir; Richard Champlin; Julianne Chen; Guillermo Garcia-Manero; Partow Kebriaei; Issa F Khouri; Ebru Koca; Marcos De Lima
Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(2):214-20.
2013: Naval Daver; Rodney Haltom; Hagop M Kantarjian; Aziz Nazha; Farhad Ravandi
Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.
Clinical lymphoma, myeloma & leukemia 2013;13(1):86-9.
2013: Keyur P Patel; Sherrie Pierce; Farhad Ravandi; Tariq Muzzafar; Carlos E Bueso-Ramos; M James You; Faisal A Khokhar; L Jeffrey Medeiros
TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013;26(2):195-203.
2013: Gautam Borthakur; Naval Daver; Stefan Faderl; Emil J Freireich; Guillermo Garcia-Manero; Tapan Kadia; Hagop Kantarjian; Farhad Ravandi; Michael G Rosenblum; Moshe Talpaz; Jorge E Cortes
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.
Haematologica 2013;98(2):217-21.
2013: Hun Ju Lee; Naval Daver; Hagop M Kantarjian; Srdan Verstovsek; Farhad Ravandi
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):327-35.
2013: Naval Daver; Jorge Cortes; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Keyur Patel; Xiao Qin Dong; Farhad Ravandi; Paolo Strati; Sa Wang; Guillermo Garcia-Manero
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
American journal of hematology 2013;88(1):56-9.
2012: Alfonso Quintás-Cardama; Farhad Ravandi; Theresa Liu-Dumlao; Sherry Pierce; Gautam Borthakur; Mark Brandt; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Hagop Kantarjian
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Blood 2012;120(24):4840-5.
2012: John Mascarenhas; Vesna Najfeld; Bruce Petersen; Nikolai Podoltsev; Raajit Rampal; Farhad Ravandi; Gail Roboz; Martin Tallman; Omar Abdel-Wahab; Dan Douer; Eric Feldman; Mark L Heaney; Elizabeth Hexner; Ronald Hoffman; Ross Levine
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Leukemia research 2012;36(12):1500-4.
2012: Yiming Chen; Jorge Cortes; Hagop Kantarjian; Haijun Wang; Farhad Ravandi
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
Cancer 2012;118(23):5811-8.
2012: Gautam Borthakur; Stefan Faderl; Tapan Kadia; Hagop Kantarjian; Rajyalakshmi Luthra; Keyur P Patel; Sherry Pierce; Wei Qiao; Farhad Ravandi; Jorge E Cortes
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.
Cancer 2012;118(23):5819-22.
2012: Tapan M Kadia; Hagop Kantarjian; Steven Kornblau; Raja Luthra; Sherry Pierce; Gautam Borthakur; Jorge Cortes; Stefan Faderl; Emil J Freireich; Guillermo Garcia-Manero; Farhad Ravandi
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
Cancer 2012;118(22):5550-9.
2012: Farhad Ravandi; Charles Alan Schiffer; Richard A Larson; Francesco Lo Coco; Frederick R Appelbaum; Alan K Burnett; Elihu H Estey; Hagop M Kantarjian
Gemtuzumab ozogamicin: time to resurrect?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(32):3921-3.
2012: Yi Zhou; L Jeffrey Medeiros; Farhad Ravandi; Sa A Wang; Jorge Cortes; Jeffrey L Jorgensen; Hagop M Kantarjian; Sergej Konoplev
Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia.
American journal of clinical pathology 2012;138(5):744-50.
2012: Y Boumber; R Castoro; Jorge Cortes; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Jean-Pierre J Issa; Elias Jabbour; J Jorgensen; Andrew Lamb; J Autry; Gautam Borthakur; S Wen; Farhad Ravandi
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
Leukemia 2012;26(11):2428-31.
2012: Farhad Ravandi
GR SNP helps transform myelofibrosis.
Blood 2012;120(15):2934-5.
2012: Gloria J Morris; Farhad Ravandi; Kristine Swartz; Andrew E Chapman; Jason S Levitz; Stuart M Lichtman; Kathryn R Chan
Senior adult oncology: three cases of advanced cancer in patients of advanced age.
Seminars in oncology 2012;39(5):e23-35.
2012: Mikako Warren; C Cameron Yin; Jorge E Cortes; Hagop M Kantarjian; Rajyalakshmi Luthra; L Jeffrey Medeiros; Farhad Ravandi; Zhuang Zuo
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012;25(10):1405-12.
2012: Theresa Liu-Dumlao; Susan O'Brien; Hagop Kantarjian; Deborah A Thomas; Farhad Ravandi
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Current oncology reports 2012;14(5):387-94.
2012: Yiming Chen; Jorge Cortes; Zeev Estrov; Stefan Faderl; Hagop Kantarjian; Farhad Ravandi; Kristy Rey; Gautam Borthakur
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Clinical lymphoma, myeloma & leukemia 2012;12(5):341-4.
2012: Stefan Faderl; Jennie Feliu; Alessandra Ferrajoli; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Jan Burger; Marina Konopleva; Farhad Ravandi; Xuemei Wang; Hagop M Kantarjian
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Cancer 2012;118(18):4471-7.
2012: Wei-Gang Tong; William Wierda; Gautam Borthakur; Carlos Bueso-Ramos; Stefan Faderl; Elias Jabbour; Tapan Kadia; Hagop Kantarjian; Sherry Pierce; Alfonso Quintás-Cardama; Farhad Ravandi; Jianqin Shan; Guillermo Garcia-Manero
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Cancer 2012;118(18):4462-70.
2012: Susan O'Brien; Farhad Ravandi; David A Rizzieri; Mikkael A Sekeres; Karin Staudacher; Adriano Venditti; Norbert Vey; Trygve Bergeland; Donald A Berry; Mike Dennis; Tove Flem Jacobsen; Utz O Krug; Francis J Giles
Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia.
British journal of haematology 2012;158(5):581-8.
2012: Maro Ohanian; Srdan Verstovsek; Cameron Yin; Zeev Estrov; Yang Huh; Hagop Kantarjian; Vasiliki Leventaki; Pei Lin; Farhad Ravandi
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.
Leukemia & lymphoma 2012;53(9):1839-41.
2012: Farhad Ravandi; Jeffrey L Jorgensen
Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(8):1029-36.
2012: Margaret R O'Donnell; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Daniel A Arber; Eyal Attar; Uma Borate; Steven E Coutre; Lloyd E Damon; Salil Goorha; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael Millenson; Joseph O Moore; Maoko Naganuma; Kristina M Gregory
Acute myeloid leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(8):984-1021.
2012: Elias Jabbour; Tapan Kadia; Marina Konopleva; Susan O'Brien; William Plunkett; Farhad Ravandi; Gautam Borthakur; Mark Brandt; Jan Burger; Jorge Cortes; Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Xuelin Huang; Hagop Kantarjian
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2012;12(4):244-51.
2012: Aziz Nazha; Sherry Pierce; Gautam Borthakur; Jorge Cortes; Naval Daver; Stefan Faderl; Tapan Kadia; Hagop Kantarjian; Raja Luthra; Farhad Ravandi
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
Haematologica 2012;97(8):1242-5.
2012: Hagop M Kantarjian; Ching-Yuan Kuo; Daniel Lysák; Jiri Mayer; Grzegorz Mazur; Mark Minden; Albert Oriol; Farhad Ravandi; Xavier G Thomas; Agnieszka Wierzbowska; Rena Buckstein; Jaroslav Cermak; Wen-Chien Chou; Jacques Delaunay; Anna Dmoszynska; Stefan Faderl; Jyh-Pyng Gau; Christopher Arthur
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(21):2670-7.
2012: Stefan Faderl; Siddhartha Ganguly; Stuart Goldberg; Jochen Greiner; Parameswaran Hari; Dirk Huebner; Madan Jagasia; Tibor Kovacsovics; Michael Maris; Farhad Ravandi; Christian Recher; David A Rizzieri; Gary Schiller; Karen Seiter; Robert Stuart; Michael Vasconcelles; Norbert Vey; Eunice S Wang; Meir Wetzler; David Avigan; Robert Collins; Michael Craig; Hagop M Kantarjian
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(20):2492-9.
2012: Shalini Verma; Farhad Ravandi; Neelima Reddy; Deborah A Thomas; Carlos E Bueso-Ramos; Wesley O Greaves; Hagop Kantarjian; Rajyalakshmi Luthra; L Jeffrey Medeiros; Susan O'Brien; Keyur P Patel
Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.
American journal of clinical pathology 2012;138(1):153-6.
2012: J Hoellenriegel; Michael J Keating; Susan O'Brien; A Pandey; Farhad Ravandi; U Sinha; M Sivina; William G Wierda; G P Coffey; Alessandra Ferrajoli; Jan A Burger
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Leukemia 2012;26(7):1576-83.
2012: Naveen Pemmaraju; Alfonso Quintas-Cardama; Farhad Ravandi; Jianqin Shan; Srdan Verstovsek; William Wierda; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jorge Cortes
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Haematologica 2012;97(7):1029-35.
2012: Guillermo Garcia-Manero; Yumin Hu; Elias Jabbour; Tapan M Kadia; Nebiyou B Bekele; Gautam Borthakur; Mark Brandt; Jorge E Cortes; Marcos de Lima; Stefan Faderl; Marina Y Konopleva; Deborah McCue; Willie Mae Newsome; Sherry R Pierce; Farhad Ravandi; Francesco Paolo Tambaro; Hui Yang; Hagop M Kantarjian
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2204-10.
2012: Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Jorge Cortes
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Cancer 2012;118(12):3116-22.
2012: Christelle Chacar; Jorge Cortes; Zeev Estrov; Elias Jabbour; Tapan Kadia; Farhad Ravandi; Mary Beth Rios; Gautam Borthakur; Hagop Kantarjian
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
Clinical lymphoma, myeloma & leukemia 2012;12(3):197-200.
2012: Farhad Ravandi; Hagop Kantarjian
Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia.
Nature reviews. Clinical oncology 2012;9(6):310-1.
2012: Alireza Eghtedar; Zeev Estrov; Stefan Faderl; Alessandra Ferrajoli; Solly George; Hagop M Kantarjian; Robert C Newton; Carol Bivins; Gautam Borthakur; Jan Burger; Jorge Cortes; Peggy A Scherle; Srdan Verstovsek; Farhad Ravandi
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood 2012;119(20):4614-8.
2012: Farhad Ravandi; Xuemei Wang; Michael Andreeff; Mark Brandt; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Tapan Kadia; Marina Konopleva; Steven Kornblau; Rajyalakshmi Luthra; Keyur Patel; Sherry Pierce; Hagop Kantarjian
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
Cancer 2012;118(10):2665-73.
2012: Tapan M Kadia; Hagop M Kantarjian; Charles Koller; Sherry Pierce; Gautam Borthakur; Mark Brandt; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Sergerrne York; Farhad Ravandi
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
British journal of haematology 2012;157(3):312-20.
2012: Michael S Mathisen; Farhad Ravandi
Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.
Future oncology (London, England) 2012;8(4):351-7.
2012: Hagop Kantarjian; Partow Kebriaei; Monica Kwari; Anjali Advani; Richard Champlin; Jorge Cortes; Stefan Faderl; Luis Fayad; Elias Jabbour; Jeffrey Jorgensen; Farhad Ravandi; Mary Beth Rios; Michael Rytting; Robert Tarnai; Deborah Thomas; Sa A Wang; Sergernne York; Susan O'Brien
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
The lancet oncology 2012;13(4):403-11.
2012: Francis Giles; Tove Flem Jacobsen; Farhad Ravandi; David Rizzieri; Ronan Swords; Susan O'Brien
Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Leukemia research 2012;36(4):e71-3.
2012: Partow Kebriaei; Rajyalakshmi Luthra; Susan O'Brien; Uday Popat; Farhad Ravandi; Gabriela Rondon; Rima M Saliba; Elizabeth Shpall; Deborah Thomas; Laura L Worth; Alexandre Chiattone; Marcos De Lima; Sergio Giralt; Roy Jones; Hagop Kantarjian; Paolo Anderlini; Borje Andersson; Richard Champlin
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18(4):584-92.
2012: Hagop Kantarjian; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Mary Beth Rios; Jenny Shan; Moshe Talpaz; Stefan Faderl; Guillermo Garcia-Manero; Xuelin Huang; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Richard Champlin; Jorge Cortes
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Blood 2012;119(9):1981-7.
2012: Alireza Eghtedar; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Hagop Kantarjian; Sherry Pierce; Farhad Ravandi; Guillermo Garcia-Manero
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.
American journal of hematology 2012;87(3):317-8.
2012: Aref Al-Kali; Mohamad Ayoubi; Mark Brandt; Jorge E Cortes; Stefan Faderl; Tapan Kadia; Hagop Kantarjian; Sergej Konoplev; Erpei Lin; Farhad Ravandi; Gautam Borthakur
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients.
Haematologica 2012;97(2):235-40.
2012: Stefan Faderl; Varsha Gandhi; Guillermo Garcia-Manero; Elias Jabbour; Gautam Borthakur; Anna L Byrd; Jorge Cortes; Zeev Estrov; Monica Kwari; Farhad Ravandi; Hagop M Kantarjian
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Cancer 2012;118(3):722-8.
2012: Farhad Ravandi
Acute myeloid leukemia as a model for cancer therapy.
Frontiers in oncology 2012;2():139.
2011: Manish Sharma; Sergio Giralt; Hagop Kantarjian; Partow Kebriaei; Marina Konopleva; Deborah McCue; Muzaffar H Qazilbash; Farhad Ravandi; Michael Andreeff; Qaiser Bashir; Ulas Darda Bayraktar; Richard E Champlin; Julianne Chen; Alexandre Chiattone; Jorge Cortes; Marcos de Lima
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(12):1874-7.
2011: Roland B Walter; Frederick R Appelbaum; Gautam Borthakur; Jorge E Cortes; Hagop A Kantarjian; Megan Othus; Sherry A Pierce; Farhad Ravandi; Elihu H Estey
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(33):4417-23.
2011: Michael S Mathisen; Farhad Ravandi
Horse versus rabbit antithymocyte globulin in aplastic anemia.
The New England journal of medicine 2011;365(19):1842; author reply 1843-4.
2011: Farhad Ravandi
Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.
British journal of haematology 2011;155(4):413-9.
2011: Kiran Naqvi; Sherry Pierce; Farhad Ravandi; Elias Jabbour; Hagop Kantarjian; Gautam Borthakur; Carlos Bueso-Ramos; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
Blood 2011;118(17):4690-3.
2011: Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Mary Beth Rios; Jenny Shan; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Blood 2011;118(17):4541-6; quiz 4759.
2011: Dushyant Verma; Srdan Verstovsek; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Mary Beth Rios; Sara S Strom; Jorge Cortes
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Blood 2011;118(16):4353-8.
2011: Farhad Ravandi; Deborah Thomas; Sergernne York; Mark Brandt; Jan Burger; Pramoda Challagundla; Stefan Faderl; Alessandra Ferrajoli; Jeffrey Jorgensen; Michael Keating; Charles Koller; Rajyalakshmi Luthra; Susan O'Brien; Sherry Pierce; Hagop Kantarjian
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Blood 2011;118(14):3818-23.
2011: Jorge Cortes; Guillermo Garcia-Manero; Elias Jabbour; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Jenny Shan; Srdan Verstovsek; Gautam Borthakur; Elizabeth Burton; Hagop Kantarjian
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Clinical lymphoma, myeloma & leukemia 2011;11(5):421-6.
2011: Tariq I Mughal; Alfonso Quintás-Cardama; Jerald P Radich; Farhad Ravandi; Tomasz Skorski; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Richard A Van Etten; Ayalew Tefferi
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
American journal of hematology 2011;86(9):811-9.
2011: Hillary Prescott; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
Expert opinion on emerging drugs 2011;16(3):407-23.
2011: Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jenny Shan; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Jorge Cortes
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3173-8.
2011: Aref Al-Kali; Mark Brandt; Jorge Cortes; Stefan Faderl; Dan Jones; Hagop Kantarjian; Sherry Pierce; Caroline Abril; Farhad Ravandi
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2011;11(4):361-6.
2011: John Schindler; Yumin Shen; Ellen Vitetta; Stefan K. Barta; Ira Braunchweig; Srikanth Gajavelli; Victor Ghetie; Samir Parekh; Farhad Ravandi; Amit Verma
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
British journal of haematology 2011;154(4):471-6.
2011: Kiran Naqvi; Hagop Kantarjian; Srdan Verstovsek; Farhad Ravandi
A potential role of ruxolitinib in leukemia.
Expert opinion on investigational drugs 2011;20(8):1159-66.
2011: Naveen Pemmaraju; Farhad Ravandi; Hagop Kantarjian; Jorge Cortes
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Cancer 2011;117(15):3293-304.
2011: Farhad Ravandi
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.
Oncology (Williston Park, N.Y.) 2011;25(8):741-3.
2011: Farshid Dayyani; Stefan Faderl; Jorge Cortes; Elias Jabbour; Hagop Kantarjian; Sarah Schellhorn Mougalian; Kiran Naqvi; Susan O'Brien; Sherry Pierce; Farhad Ravandi; Jianqin Shan; Deborah Thomas; Jeffrey Weinberg; William Wierda; Guillermo Garcia-Manero
Prediction model for mortality after intracranial hemorrhage in patients with leukemia.
American journal of hematology 2011;86(7):546-9.
2011: Yiming Chen; Jorge Cortes; Marcos De Lima; Zeev Estrov; Stefan Faderl; Guillermo Garcia-Manero; Xuelin Huang; Tapan Kadia; Hagop Kantarjian; Partow Kebriaei; Sherry Pierce; Wei Qiao; Lynne Abruzzo; Farhad Ravandi
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(18):2507-13.
2011: Farhad Ravandi
New treatments and strategies in acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2011;11 Suppl 1():S60-4.
2011: Jan A Burger; Mariela Sivina; Farhad Ravandi
The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.
Leukemia & lymphoma 2011;52 Suppl 2():94-8.
2011: Farhad Ravandi
Chemo-immunotherapy for hairy cell leukemia.
Leukemia & lymphoma 2011;52 Suppl 2():72-4.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Gautam Borthakur; Farhad Ravandi; Srdan Verstovsek; Jianqin Shan; Jorge Cortes
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Haematologica 2011;96(6):918-21.
2011: Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Cancer 2011;117(10):2145-55.
2011: Farhad Ravandi
HCL: insights into biology.
Blood 2011;117(18):4682-3.
2011: Ali Al Ameri; Elias Jabbour; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Jianqin Shan; Sherry Pierce; Jorge Cortes; Hagop Kantarjian
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Clinical lymphoma, myeloma & leukemia 2011;11(2):237-41.
2011: Farhad Ravandi
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.
Clinical lymphoma, myeloma & leukemia 2011;11(2):198-203.
2011: Farhad Ravandi
Novel treatments in acute myeloid leukemia.
Clinical advances in hematology & oncology : H&O 2011;9(4):333-4.
2011: Farhad Ravandi
Therapy-related acute promyelocytic leukemia.
Haematologica 2011;96(4):493-5.
2011: Isam Abdel-Karim; William K Plunkett; Susan O'Brien; Francis Giles; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Min Du; Karen B Schneck; Victor J Chen; Boris K Lin; Steven J Nicol; Hagop M Kantarjian
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.
Investigational new drugs 2011;29(2):323-31.
2011: Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev Estrov; Srdan Verstovsek; Susan O'Brien; Stefan Faderl; Deborah A Thomas; John J Wright; Jorge Cortes
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Cancer 2011;117(6):1236-44.
2011: Margaret R O'Donnell; Camille N Abboud; Jessica Altman; Frederick R Appelbaum; Steven E Coutre; Lloyd E Damon; James M Foran; Salil Goorha; Lori J Maness; Guido Marcucci; Peter Maslak; Michael M Millenson; Joseph O Moore; Farhad Ravandi; Paul J Shami; B Douglas Smith; Richard M Stone; Stephen A Strickland; Martin S Tallman; Eunice S Wang
Acute myeloid leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(3):280-317.
2011: Fabio P S Santos; Hagop Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi
The search for better prognostic models in myelodysplastic syndromes.
Current hematologic malignancy reports 2011;6(1):13-21.
2011: Fabio P S Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O'Brien; Gloria N Mattiuzzi; Farhad Ravandi; Gautam Borthakur; Jorge Cortes
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
Cancer 2011;117(5):982-91.
2011: Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jenny Shan; Guillermo Garcia-Manero; William Wierda; Farhad Ravandi; Gautam Borthakur; Mary Beth Rios; Jorge Cortes
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Blood 2011;117(6):1822-7.
2011: Stefan Faderl; Deborah Ann Thomas; Susan O'Brien; Farhad Ravandi; Guillermo Garcia-Manero; Gautam Borthakur; Alessandra Ferrajoli; Srdan Verstovsek; Mohamed Ayoubi; Michael Rytting; Jennie Feliu; Hagop M Kantarjian
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Clinical lymphoma, myeloma & leukemia 2011;11(1):54-9.
2011: Farhad Ravandi
Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(4):349-51.
2011: Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Cancer 2011;117(3):572-80.
2011: Bing Z Carter; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Deborah A Thomas; Farhad Ravandi; Hagop M Kantarjian; Erich Koller; Michael Andreeff; Steven M Kornblau
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
Blood 2011;117(3):780-7.
2011: Keyur P Patel; Farhad Ravandi; Deqin Ma; Abhaya Paladugu; Bedia A Barkoh; L Jeffrey Medeiros; Rajyalakshmi Luthra
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
American journal of clinical pathology 2011;135(1):35-45.
2011: Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Haematologica 2011;96(1):62-8.
2011: Farshid Dayyani; Hagop Kantarjian; Susan O'Brien; Sherry Pierce; Dan Jones; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes; Farhad Ravandi
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Cancer 2011;117(1):110-5.
2010: Farhad Ravandi; Jorge Cortes; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Fabio P S Santos; Jianqin Shan; Mark Brandt; Marcos De Lima; Sherry Pierce; Hagop Kantarjian
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
Blood 2010;116(26):5818-23; quiz 6153.
2010: Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; Sherry Pierce; Jianquin Shan; Jorge Cortes; Susan O'Brien
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration.
Cancer 2010;116(24):5568-74.
2010: Fabio P S Santos; Carlos E Bueso-Ramos; Farhad Ravandi
Acute erythroleukemia: diagnosis and management.
Expert review of hematology 2010;3(6):705-18.
2010: Andrew Lamb; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William G Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.
Blood 2010;116(22):4422-9.
2010: Michael Rytting; Farhad Ravandi; Elihu Estey; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; Souzanne Ouzounian; Sherry Pierce; Andrew Lamb
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
Cancer 2010;116(22):5272-8.
2010: Zhuang Zuo; Dan Jones; Hui Yao; Deborah A Thomas; Susan O'Brien; Farhad Ravandi; Hagop M Kantarjian; Lynne V Abruzzo; L Jeffrey Medeiros; Su S Chen; Rajyalakshmi Luthra
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2010;23(11):1524-34.
2010: Martin S Tallman; Dan Douer; Steven D Gore; Bayard L Powell; Farhad Ravandi; Jacob Rowe; Aarati Ranganathan; Miguel A Sanz
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Clinical lymphoma, myeloma & leukemia 2010;10 Suppl 3():S122-6.
2010: Deborah Thomas; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Elias Jabbour; Sherry Pierce; Jorge Cortes; Andrew Lamb
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
Cancer 2010;116(19):4580-9.
2010: Farhad Ravandi; Susan O'Brien; Deborah Thomas; Stefan Faderl; Dan Jones; Rebecca Garris; Samuel Dara; Jeffrey Jorgensen; Partow Kebriaei; Richard Champlin; Gautam Borthakur; Jan Burger; Alessandra Ferrajoli; Guillermo Garcia-Manero; William Wierda; Jorge Cortes; Andrew Lamb
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Blood 2010;116(12):2070-7.
2010: Amit Lahoti; Andrew Lamb; Abdulla K Salahudeen; Farhad Ravandi; Jorge E Cortes; Stefan Faderl; Susan O'Brien; William G Wierda; Gloria N Mattiuzzi
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Cancer 2010;116(17):4063-8.
2010: Deborah A Thomas; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William G Wierda; Farhad Ravandi; Srdan Verstovsek; Jeffrey L Jorgensen; Carlos E Bueso-Ramos; Michael Andreeff; Sherry Pierce; Rebecca Garris; Michael J Keating; Jorge Cortes; Hagop M Kantarjian
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3880-9.
2010: Elias Jabbour; Guillermo Garcia-Manero; Nicolas Batty; Jenny Shan; Susan O'Brien; Jorge Cortes; Farhad Ravandi; Jean-Pierre J Issa; Andrew Lamb
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Cancer 2010;116(16):3830-4.
2010: Kumudha Balakrishnan; Dushyant Verma; Susan O'Brien; John Michael Kilpatrick; Yuling Chen; Brenita F Tyler; Susan Bickel; Shanta Bantia; Michael J Keating; Andrew Lamb; Varsha Gandhi; Farhad Ravandi
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Blood 2010;116(6):886-92.
2010: Farhad Ravandi
Dasatinib, an immunomodulator?
Blood 2010;116(5):673-4.
2010: Aref Al-Kali; Varsha Gandhi; Mohamad Ayoubi; Michael Keating; Farhad Ravandi
Forodesine: review of preclinical and clinical data.
Future oncology (London, England) 2010;6(8):1211-7.
2010: Fabio P S Santos; Andrew Lamb; Carmen Fava; Susan O'Brien; Guillermo Garcia-Manero; Farhad Ravandi; William G Wierda; Deborah Thomas; Jianquin Shan; Jorge Cortes
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
British journal of haematology 2010;150(3):303-12.
2010: Wei-Gang Tong; Andrew Lamb; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Gautam Borthakur; Jianqin Shan; Sherry Pierce; Mary Beth Rios; Jorge Cortes
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Cancer 2010;116(13):3152-9.
2010: Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
British journal of haematology 2010;150(1):72-82.
2010: G Nicolas Batty; Andrew Lamb; Jean-Pierre J Issa; Elias Jabbour; Fabio P S Santos; Deborah McCue; Guillermo Garcia-Manero; Sherry Pierce; Susan O'Brien; Jorge E Cortés; Farhad Ravandi
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Clinical lymphoma, myeloma & leukemia 2010;10(3):205-10.
2010: Stefan Faderl; Guillermo Garcia-Manero; Zeev Estrov; Farhad Ravandi; Gautam Borthakur; Jorge E Cortes; Susan O'Brien; Varsha Gandhi; William Plunkett; Anna Byrd; Monica Kwari; Hagop M Kantarjian
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2755-60.
2010: Pranil Chandra; Rajyalakshmi Luthra; Zhuang Zuo; Hui Yao; Farhad Ravandi; Neeli Reddy; Guillermo Garcia-Manero; Hagop Kantarjian; Dan Jones
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.
American journal of clinical pathology 2010;133(5):686-93.
2010: Dushyant Verma; Andrew Lamb; Stefan Faderl; Susan O'Brien; Sherry Pierce; Khanh Vu; Emil Freireich; Michael Keating; Jorge Cortes; Farhad Ravandi
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome.
Leukemia & lymphoma 2010;51(5):778-82.
2010: Farhad Ravandi; Jorge E Cortes; Daniel Jones; Stefan Faderl; Guillermo Garcia-Manero; Marina Konopleva; Susan O'Brien; Zeev Estrov; Gautam Borthakur; Deborah Thomas; Sherry R Pierce; Mark Brandt; Anna Byrd; B Nebiyou Bekele; Keith William Pratz; Rajyalakshmi Luthra; Mark Levis; Michael Andreeff; Hagop M Kantarjian
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(11):1856-62.
2010: Roland B Walter; Hagop M Kantarjian; Xuelin Huang; Sherry A Pierce; Zhuoxin Sun; Holly M Gundacker; Farhad Ravandi; Stefan H Faderl; Martin S Tallman; Frederick R Appelbaum; Elihu H Estey
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1766-71.
2010: Nikolay D Dimov; L Jeffrey Medeiros; Farhad Ravandi; Carlos E Bueso-Ramos
Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.
American journal of clinical pathology 2010;133(3):484-90.
2010: Hagop M Kantarjian; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Guillermo Garcia-Manero; Jianquin Shan; Sherry Pierce; Jorge Cortes; Susan O'Brien
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission.
Leukemia & lymphoma 2010;51(3):475-80.
2010: Jan A Burger; N S Velev; Elias Jabbour; William G Wierda; Farhad Ravandi; Jorge E Cortes; Andrew Lamb; Y L Nieto; Elizabeth J Shpall; Jeffrey L Jorgensen
Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells.
Leukemia 2010;24(3):666-8.
2010: Dan Jones; Hui Yao; Angela Romans; Caroline Dando; Sherry Pierce; Gautam Borthakur; Amy Hamilton; Carlos Bueso-Ramos; Farhad Ravandi; Guillermo Garcia-Manero; Andrew Lamb
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias.
Genes, chromosomes & cancer 2010;49(2):182-91.
2010: Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Andrew Lamb
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):398-404.
2010: Nikolay D Dimov; L Jeffrey Medeiros; Hagop M Kantarjian; Jorge E Cortes; Kun-Sang Chang; Carlos E Bueso-Ramos; Farhad Ravandi
Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.
Cancer 2010;116(2):369-76.
2010: Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Robert Westwood; Simon R Green; Judy H Chiao; Patricia A Boone; Jorge Cortes; William Plunkett
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):285-91.
2010: Gautam Borthakur; Xuelin Huang; Andrew Lamb; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre J Issa
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Leukemia & lymphoma 2010;51(1):73-8.
2010: Fabio P S Santos; Andrew Lamb; Guillermo Garcia-Manero; Jean-Pierre J Issa; Farhad Ravandi
Decitabine in the treatment of myelodysplastic syndromes.
Expert review of anticancer therapy 2010;10(1):9-22.
2010: Ali Al Ameri; Charles Koller; Andrew Lamb; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Sherry Pierce; Gloria N Mattiuzzi
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cancer 2010;116(1):93-7.
2009: Farhad Ravandi; Jean-Pierre J Issa; Guillermo Garcia-Manero; Susan O'Brien; Sherry Pierce; Jianqin Shan; Gautam Borthakur; Srdan Verstovsek; Stefan Faderl; Jorge Cortes; Andrew Lamb
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Cancer 2009;115(24):5746-51.
2009: Fabio P S Santos; Farhad Ravandi
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Leukemia & lymphoma 2009;50 Suppl 2():16-26.
2009: F P S Santos; Stefan Faderl; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Susan O'Brien; Sherry Pierce; Emil J Freireich; Xuelin Huang; Gautam Borthakur; Carlos E Bueso-Ramos; Marcos De Lima; Michael Keating; Jorge Cortes; Andrew Lamb; Farhad Ravandi
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
Leukemia 2009;23(12):2275-80.
2009: Andrew Lamb; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl; Carlos E Bueso-Ramos; Lynne V Abruzzo; Sherry Pierce; Jianqin Shan; Jean-Pierre J Issa; Guillermo Garcia-Manero
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Cancer 2009;115(22):5202-9.
2009: Farhad Ravandi; Ahmed Aribi; Susan O'Brien; Stefan Faderl; Dan Jones; Alessandra Ferrajoli; Xuelin Huang; Sergernne York; Sherry Pierce; William G Wierda; Dimitrios Kontoyiannis; Srdan Verstovsek; Barbara Pro; Luis Fayad; Michael Keating; Andrew Lamb
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5425-30.
2009: Paul Armistead; Marcos De Lima; Sherry Pierce; Wei Qiao; Xuemei Wang; Peter F Thall; Sergio Giralt; Farhad Ravandi; Andrew Lamb; Richard Champlin; Elihu Estey
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(11):1431-8.
2009: Farhad Ravandi; Partow Kebriaei
Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hematology/oncology clinics of North America 2009;23(5):1043-63, vi.
2009: Deborah A Thomas; Farhad Ravandi; Michael Keating; Hagop M Kantarjian
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy.
Leukemia & lymphoma 2009;50 Suppl 1():27-31.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos E Bueso-Ramos; Srdan Verstovsek
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4760-6.
2009: Gautam Borthakur; Edward Lin; Nitin Jain; Elihu E Estey; Jorge E Cortes; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Sherry Pierce; Andrew Lamb
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
Cancer 2009;115(14):3217-21.
2009: Farhad Ravandi
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Leukemia & lymphoma 2009;50(7):1073-4.
2009: Alfonso Quintás-Cardama; Jorge E Cortes; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; David Liu; Eric Bleickardt; Tai-Tsang Chen; Hagop M Kantarjian
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Cancer 2009;115(13):2912-21.
2009: R Garg; Stefan Faderl; Guillermo Garcia-Manero; Jorge Cortes; Charles Koller; X Huang; S York; Sherry Pierce; M Brandt; Miloslav Beran; Gautam Borthakur; Andrew Lamb; Farhad Ravandi
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
Leukemia 2009;23(7):1297-302.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Farhad Ravandi; Susan O'Brien; Deborah Thomas; Gabriela Vidal-Senmache; William G Wierda; Steven M Kornblau; Jorge Cortes
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Cancer 2009;115(11):2482-90.
2009: L De Padua Silva; Marcos De Lima; Andrew Lamb; Stefan Faderl; Partow Kebriaei; Sergio Giralt; Jan Davisson; Guillermo Garcia-Manero; Richard Champlin; Jean-Pierre J Issa; Farhad Ravandi
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
Bone marrow transplantation 2009;43(11):839-43.
2009: Carmen Fava; Hagop M Kantarjian; Elias Jabbour; Susan O'Brien; Nitin Jain; Mary Beth Rios; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Jianqin Shan; Jorge Cortes
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2009: Ravin Garg; Andrew Lamb; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Denise Lovshe; Sherry Pierce; Susan O'Brien
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.
Cancer 2009;115(10):2147-54.
2009: Arturo Vega-Ruiz; Stefan Faderl; Zeev Estrov; Sherry Pierce; Jorge Cortes; Andrew Lamb; Farhad Ravandi
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
International journal of hematology 2009;89(4):489-96.
2009: Yang O Huh; L Jeffrey Medeiros; Farhad Ravandi; Sergej Konoplev; Jeffrey L Jorgensen; Roberto N Miranda
T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases.
American journal of clinical pathology 2009;131(3):347-56.
2009: Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Andrew Lamb
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):504-10.
2009: Farhad Ravandi
Hairy cell leukemia.
Clinical lymphoma & myeloma 2009;9 Suppl 3():S254-9.
2009: Wanlong Ma; Andrew Lamb; Xi Zhang; Iman Jilani; Mohammad Sheikholeslami; Amber C Donahue; Farhad Ravandi; Elihu Estey; Susan O'Brien; Michael Keating; Francis Giles; Maher Albitar
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Cancer biomarkers : section A of Disease markers 2009;5(1):51-8.
2009: Srdan Verstovsek; Ayalew Tefferi; Andrew Lamb; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Patricia Ault; Carlos Bueso-Ramos; Jorge E Cortes
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):368-73.
2009: Dushyant Verma; Susan O'Brien; Deborah Thomas; Stefan Faderl; Charles Koller; Sherry Pierce; Partow Kebriaei; Guillermo Garcia-Manero; Jorge Cortes; Andrew Lamb; Farhad Ravandi
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer 2009;115(1):101-6.
2008: Dan Jones; Rajyalakshmi Luthra; Jorge Cortes; Deborah Thomas; Susan O'Brien; Carlos Bueso-Ramos; Seema Hai; Farhad Ravandi; Marcos de Lima; Andrew Lamb; Jeffrey L Jorgensen
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
Blood 2008;112(13):5190-2.
2008: Shahram Mori; Jorge Cortes; Andrew Lamb; Weiguo Zhang; Michael Andreef; Farhad Ravandi
Potential role of sorafenib in the treatment of acute myeloid leukemia.
Leukemia & lymphoma 2008;49(12):2246-55.
2008: Gautam Borthakur; Andrew Lamb; Xuemei Wang; William Plunkett; Varsha Gandhi; Stefan Faderl; Guillermo Garcia-Manero; Farhad Ravandi; Sherry Pierce; Elihu H Estey
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.
Cancer 2008;113(11):3181-5.
2008: Susan O'Brien; Deborah Thomas; Farhad Ravandi; Stefan Faderl; Jorge Cortes; Gautam Borthakur; Sherry Pierce; Guillermo Garcia-Manero; Hagop M Kantarjian
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
Cancer 2008;113(11):3186-91.
2008: Margaret R O'Donnell; Frederick R Appelbaum; Steven E Coutre; Lloyd E Damon; Harry P Erba; James Foran; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Peter Maslak; Michael Millenson; Joseph O Moore; Farhad Ravandi; Friedrich Schuening; Paul Shami; B Douglas Smith; Richard M Stone; Martin S Tallman; Eunice S Wang; Frank L White
Acute myeloid leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(10):962-93.
2008: Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Xuelin Huang; Srdan Verstovsek; Farhad Ravandi; Zeev Estrov; Gautam Borthakur; Monica Kwari; Hagop M Kantarjian
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer 2008;113(8):2090-6.
2008: Susan O'Brien; Deborah A Thomas; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Andrew Lamb
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
Cancer 2008;113(8):2097-101.
2008: Masamitsu Yanada; Gautam Borthakur; Guillermo Garcia-Manero; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Andrew Lamb; Elihu Estey
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.
Leukemia research 2008;32(10):1505-9.
2008: Andrew Lamb; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan F List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre J Issa; Emil J Freireich; Guillermo Garcia-Manero
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Cancer 2008;113(6):1351-61.
2008: Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008;112(5):1638-45.
2008: Arturo Vega-Ruiz; Susan O'Brien; Jorge Cortes; Partow Kebriaei; Deborah Thomas; Andrew Lamb; Farhad Ravandi
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Leukemia research 2008;32(9):1468-71.
2008: Masamitsu Yanada; Gautam Borthakur; Farhad Ravandi; Carlos Bueso-Ramos; Andrew Lamb; Elihu Estey
Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.
Haematologica 2008;93(8):1263-5.
2008: Constantine S Tam; Andrew Lamb; Guillermo Garcia-Manero; Gautam Borthakur; Susan O'Brien; Farhad Ravandi; Jianqin Shan; Jorge Cortes
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Blood 2008;112(3):516-8.
2008: Wendy Stock; Samir D Undevia; Carol Bivins; Farhad Ravandi; Olatoyosi Odenike; Stefan Faderl; Elizabeth Rich; Gautam Borthakur; Lucy Godley; Srdan Verstovsek; Andrew Artz; William Wierda; Richard A Larson; Yanming Zhang; Jorge Cortes; Mark J Ratain; Francis Giles
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Elias Jabbour; Andrew Lamb; Dan Jones; Megan Breeden; Guillermo Garcia-Manero; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Jorge Cortes
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Blood 2008;112(1):53-5.
2008: A Quintás-Cardama; W Tong; Andrew Lamb; D Thomas; Farhad Ravandi; S Kornblau; Taghi Manshouri; J E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Leukemia 2008;22(5):965-70.
2008: Gautam Borthakur; Samih El Ahdab; Farhad Ravandi; Stefan Faderl; Alessandra Ferrajoli; Beth Newman; Jean-Pierre J Issa; Andrew Lamb
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Leukemia & lymphoma 2008;49(4):690-5.
2008: Masamitsu Yanada; Guillermo Garcia-Manero; Gautam Borthakur; Farhad Ravandi; Andrew Lamb; Elihu Estey
Relapse and death during first remission in acute myeloid leukemia.
Haematologica 2008;93(4):633-4.
2008: Guillermo Garcia-Manero; Jianqin Shan; Stefan Faderl; Jorge Cortes; Farhad Ravandi; Gautam Borthakur; William G Wierda; Sherry Pierce; Elihu Estey; Jinsong Liu; X Huang; Andrew Lamb
A prognostic score for patients with lower risk myelodysplastic syndrome.
Leukemia 2008;22(3):538-43.
2008: Susan O'Brien; Farhad Ravandi; Todd Riehl; William Wierda; Xuelin Huang; Jeffrey Tarrand; Brandi O'Neal; Andrew Lamb; Michael Keating
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
Blood 2008;111(4):1816-9.
2008: Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.
Blood 2008;111(1):328-37.
2007: Masamitsu Yanada; Guillermo Garcia-Manero; Gautam Borthakur; Farhad Ravandi; Andrew Lamb; Elihu Estey
Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.
Cancer 2007;110(12):2756-60.
2007: Farhad Ravandi; Alan K Burnett; Edward D Agura; Hagop M Kantarjian
Progress in the treatment of acute myeloid leukemia.
Cancer 2007;110(9):1900-10.
2007: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Masamitsu Yanada; Xuelin Huang; Guillermo Garcia-Manero; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; Stefan Faderl; Jean-Pierre J Issa; Andrew Lamb; Elihu Estey
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
British journal of haematology 2007;138(4):555-7.
2007: Farhad Ravandi; Stefan Faderl; Partow Kebriaei; Andrew Lamb
Modern treatment programs for adults with acute lymphoblastic leukemia.
Current hematologic malignancy reports 2007;2(3):169-75.
2007: Ahmed Aribi; Carlos E Bueso-Ramos; Elihu Estey; Zeev Estrov; Susan O'Brien; Francis Giles; Stefan Faderl; Deborah Thomas; Partow Kebriaei; Guillermo Garcia-Manero; Sherry Pierce; Jorge Cortes; Andrew Lamb; Farhad Ravandi
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Ahmed Aribi; Yang Huh; Michael Keating; Susan O'Brien; Alessandra Ferrajoli; Stefan Faderl; William G Wierda; Andrew Lamb; Farhad Ravandi
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Leukemia research 2007;31(7):939-45.
2007: William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Andrew Lamb; Michael Keating
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Farhad Ravandi; Iman Jilani; Elihu Estey; Andrew Lamb; A Dey; C Aguilar; C Jitkaroon; Francis Giles; Susan O'Brien; Michael Keating; Maher Albitar
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Leukemia research 2007;31(6):791-7.
2007: Andrew Lamb; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Francis Giles; Jorge Cortes
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Elias Jabbour; Susan O'Brien; Andrew Lamb; Guillermo Garcia-Manero; Alessandra Ferrajoli; Farhad Ravandi; Maria Cabanillas; Deborah A Thomas
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
Blood 2007;109(8):3214-8.
2007: Hagop M Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farhad Ravandi; Jorge Cortes; Jianqin Shan; Jan Davisson; Carlos E Bueso-Ramos; Jean-Pierre J Issa
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Cancer 2007;109(6):1133-7.
2007: Ahmed Aribi; Gautam Borthakur; Farhad Ravandi; Jianqin Shan; Jan Davisson; Jorge Cortes; Andrew Lamb
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Cancer 2007;109(4):713-7.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Francis Giles; Deborah Thomas; William G Wierda; Jorge Cortes
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Francis Giles; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Sherry Pierce; Maher Albitar; Jorge Cortes; Andrew Lamb
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: Hagop M Kantarjian; Susan O'Brien; Jianqin Shan; Ahmed Aribi; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Jan Davisson; Jean-Pierre J Issa
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Cancer 2007;109(2):265-73.
2007: Gail J Roboz; Francis Giles; Ellen K Ritchie; Sandra Allen-Bard; Tania J Curcio; Meredith A Wilkes; S Lani Park; Hagop M Kantarjian; Stefan Faderl; Farhad Ravandi; Michael J Kelner; Eric J Feldman
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):10-5.
2007: Francis Giles; David A Rizzieri; Judith E Karp; Norbert Vey; Farhad Ravandi; Stefan Faderl; Khuda Dad Khan; Gregor Verhoef; Pierre W Wijermans; Anjali Advani; Gail J Roboz; Andrew Lamb; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Ghulam Mufti; Susan O'Brien
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2007: Andrew Lamb; Yasuhiro Oki; Guillermo Garcia-Manero; Xuelin Huang; Susan O'Brien; Jorge Cortes; Stefan Faderl; Carlos E Bueso-Ramos; Farhad Ravandi; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Jianqin Shan; Jan Davis; Francis Giles; Hussain I Saba; Jean-Pierre J Issa
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2006: Farhad Ravandi; Varsha Gandhi
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Expert opinion on investigational drugs 2006;15(12):1601-13.
2006: Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'Brien; Elihu Estey; Carlos E Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre J Issa
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Farhad Ravandi; Susan O'Brien
Alemtuzumab in CLL and other lymphoid neoplasms.
Cancer investigation 2006;24(7):718-25.
2006: Deborah A Thomas; Farhad Ravandi; Andrew Lamb
Monoclonal antibody therapy for hairy cell leukemia.
Hematology/oncology clinics of North America 2006;20(5):1125-36.
2006: Alfonso Quintas-Cardama; Andrew Lamb; Susan O'Brien; Elias Jabbour; Francis Giles; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Jianqin Shan; Srdan Verstovsek; Jorge Cortes
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Kumudha Balakrishnan; Ramadevi Nimmanapalli; Farhad Ravandi; Michael J Keating; Varsha Gandhi
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Blood 2006;108(7):2392-8.
2006: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Daniel Jones; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Karen W L Yee; Zhihong Zeng; Marina Konopleva; Srdan Verstovsek; Farhad Ravandi; Alessandra Ferrajoli; Deborah Thomas; William G Wierda; Efrosyni Apostolidou; Maher Albitar; Susan O'Brien; Michael Andreeff; Francis Giles
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5165-73.
2006: Francis Giles; Thomas Fischer; Jorge Cortes; Guillermo Garcia-Manero; Joachim Beck; Farhad Ravandi; Eric Masson; Patricia Rae; Glen Laird; Sunil Sharma; Andrew Lamb; Margaret Dugan; Maher Albitar; Kapil N Bhalla
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4628-35.
2006: Francis Giles; Srdan Verstovsek; Guillermo Garcia-Manero; Deborah Thomas; Farhad Ravandi; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Elias Jabbour; Jianqin Shan; Susan O'Brien; Maher Albitar; Andrew Lamb
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Stefan Faderl; Srdan Verstovsek; Jorge Cortes; Farhad Ravandi; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Charles Koller; Francis Giles; William G Wierda; Monica Kwari; Hagop M Kantarjian
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Francis Giles; William T Bellamy; Zeev Estrov; Susan M O'Brien; Srdan Verstovsek; Farhad Ravandi; Miloslav Beran; Paul Bycott; Yazdi K Pithavala; Heidi M Steinfeldt; Steven D Reich; Alan F List; Karen W L Yee
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leukemia research 2006;30(7):801-11.
2006: Raoul Tibes; Michael J Keating; Alessandra Ferrajoli; William G Wierda; Farhad Ravandi; Guillermo Garcia-Manero; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Mary L Browning; Stefan Faderl
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2006: Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles Koller; Stefan Faderl; Francis Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Eileen Hacker Danaher; Carol J Ferrans; Ellen Verlen; Farhad Ravandi; Koen van Besien; Julie Gelms; Natalie Dieterle
Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant.
Oncology nursing forum 2006;33(3):614-24.
2006: Andrew Lamb; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain I Saba
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Cancer 2006;106(8):1794-803.
2006: Farhad Ravandi
Treatment of acute myeloid leukemia in older adults: time to reflect?
Leukemia & lymphoma 2006;47(4):579-80.
2006: Razelle Kurzrock; Farhad Ravandi
Purine analogues in advanced T-cell lymphoid malignancies.
Seminars in hematology 2006;43(2 Suppl 2):S27-34.
2006: Nicholas Di Bella; Farhad Ravandi
Purine analogue combinations for indolent lymphomas.
Seminars in hematology 2006;43(2 Suppl 2):S11-21.
2006: Ahmed Aribi; Farhad Ravandi; Francis Giles
Novel agents in acute myeloid leukemia.
Cancer journal (Sudbury, Mass.) 2006;12(2):77-91.
2006: Yasuhiro Oki; Hagop M Kantarjian; Xian Zhou; Jorge Cortes; Stefan Faderl; Srdan Verstovsek; Susan O'Brien; Charles Koller; Miloslav Beran; B Nebiyou Bekele; Sherry Pierce; Deborah Thomas; Farhad Ravandi; William G Wierda; Francis Giles; Alessandra Ferrajoli; Elias Jabbour; Michael J Keating; Carlos E Bueso-Ramos; Elihu Estey; Guillermo Garcia-Manero
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Farhad Ravandi; Susan O'Brien
Immune defects in patients with chronic lymphocytic leukemia.
Cancer immunology, immunotherapy : CII 2006;55(2):197-209.
2006: Farhad Ravandi; Zeev Estrov
Eradication of leukemia stem cells as a new goal of therapy in leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):340-4.
2006: Farhad Ravandi; Stefan Faderl
Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
Leukemia research 2006;30(1):103-5.
2005: Farhad Ravandi; Susan O'Brien
Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.
Mayo Clinic proceedings. Mayo Clinic 2005;80(12):1660-74.
2005: Farhad Ravandi; Susan O'Brien; Dan Jones; Susan Lerner; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Guillermo Garcia-Manero; Deborah Thomas; Charles Koller; Srdan Verstovsek; Francis Giles; Jorge Cortes; Marco Herling; Andrew Lamb; Michael Keating
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: Francis Giles; Srdan Verstovsek; Deborah Thomas; Stanton Gerson; Jorge Cortes; Stefan Faderl; Alessandra Ferrajoli; Farhad Ravandi; Steven M Kornblau; Guillermo Garcia-Manero; Elias Jabbour; Susan O'Brien; Verena Karsten; Ann Cahill; Karen Yee; Maher Albitar; Mario Sznol; Andrew Lamb
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Farhad Ravandi; Andrew Lamb; Dan Jones; Claire Dearden; Michael Keating; Susan O'Brien
Mature T-cell leukemias.
Cancer 2005;104(9):1808-18.
2005: Farhad Ravandi; Susan O'Brien
Infections associated with purine analogs and monoclonal antibodies.
Blood reviews 2005;19(5):253-73.
2005: Farhad Ravandi; Susan O'Brien
Alemtuzumab.
Expert review of anticancer therapy 2005;5(1):39-51.
2005: Farhad Ravandi; Partow Kebriaei
Cytokines in the treatment of acute leukemias.
Cancer treatment and research 2005;126():313-31.
2004: Simrit Parmar; Efstratios Katsoulidis; Amit Verma; Yongzhong Li; Antonella Sassano; Lakhvir Lal; Beata Majchrzak; Farhad Ravandi; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
The Journal of biological chemistry 2004;279(24):25345-52.
2004: Mohamad A Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M Rifkin; Ralph Ellison
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
British journal of haematology 2004;125(4):470-6.
2004: Farhad Ravandi; Andrew Lamb; Francis Giles; Jorge Cortes
New agents in acute myeloid leukemia and other myeloid disorders.
Cancer 2004;100(3):441-54.
2004: Shrihari S. Kadkol; Annette Bruno; Carol Dodge; Valerie Lindgren; Farhad Ravandi
Comprehensive analysis of CBFbeta-MYH11 fusion transcripts in acute myeloid leukemia by RT-PCR analysis.
The Journal of molecular diagnostics : JMD 2004;6(1):22-7.
2004: Farhad Ravandi; Jorge Cortes
Investigational agents in myeloid disorders.
Advances in pharmacology (San Diego, Calif.) 2004;51():59-97.
2003: Farhad Ravandi; Shrihari S. Kadkol; J Ridgeway; Annette Bruno; C Dodge; Valerie Lindgren
Molecular identification of CBFbeta-MYH11 fusion transcripts in an AML M4Eo patient in the absence of inv16 or other abnormality by cytogenetic and FISH analyses--a rare occurrence.
Leukemia 2003;17(9):1907-10.
2003: Koen van Besien; Steven M Devine; Amittha Wickrema; Ellen Jessop; K Amin; M Yassine; Vera Maynard; Wendy Stock; David J Peace; Farhad Ravandi; Yi-Hsiang Chen; Ronald Hoffman; J Sossman
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
Bone marrow transplantation 2003;32(5):471-6.
2003: Farhad Ravandi; Amit Verma; Jean Ridgeway; Kenneth Pursell
Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications.
Leukemia research 2003;27(9):853-7.
2003: Koen van Besien; Steven M Devine; Amittha Wickrema; Ellen Jessop; K Amin; M Yassine; Vera Maynard; Wendy Stock; David J Peace; Farhad Ravandi; Yi-Hsiang Chen; T Cheung; S Vijayakumar; Ronald Hoffman; Jeffrey A Sosman
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
Bone marrow transplantation 2003;32(1):9-13.
2003: Marcos De Lima; Farhad Ravandi; Munir Shahjahan; Borje Andersson; Daniel Couriel; Michele Donato; Issa Khouri; James L Gajewski; Koen van Besien; Richard Champlin; Sergio Giralt; Andrew Lamb
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
Cancer 2003;97(5):1242-7.
2003: Farhad Ravandi; Moshe Talpaz; Zeev Estrov
Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):535-50.
2002: Amit Verma; Mani Mohindru; Dilip K Deb; Antonella Sassano; Suman Kambhampati; Farhad Ravandi; Saverio Minucci; Dhan V Kalvakolanu; Leonidas C Platanias
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide.
The Journal of biological chemistry 2002;277(47):44988-95.
2002: Farhad Ravandi; Jorge Cortes; Zeev Estrov; Deborah Thomas; Francis Giles; Yang O Huh; Sherry Pierce; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Leukemia research 2002;26(7):643-9.
2002: Farhad Ravandi; Moshe Talpaz; Andrew Lamb; Zeev Estrov
Cellular signalling pathways: new targets in leukaemia therapy.
British journal of haematology 2002;116(1):57-77.
2001: IA Mayer; Amit Verma; IM Grumbach; Shahab Uddin; Fatima Lekmine; Farhad Ravandi; Beata Majchrzak; S Fujita; Eleanor N Fish; Leonidas C Platanias
The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells.
The Journal of biological chemistry 2001;276(30):28570-7.
2001: Farhad Ravandi; Andrew Lamb; Agueda Cohen; M Davis; Susan O'Brien; Paolo Anderlini; Borje Andersson; David F Claxton; Michele Donato; James L Gajewski; Issa Khouri; Martin Korbling; Naoto T Ueno; D deVos; Richard Champlin; Sergio Giralt
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.
Bone marrow transplantation 2001;27(12):1221-5.
2001: Farhad Ravandi; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Francis Giles; Deborah Thomas; Jorge Cortes; Michael Andreeff; Zeev Estrov; Mary Beth Rios; Maher Albitar
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: Farhad Ravandi; Kimberly Hayes; Jorge Cortes; Maher Albitar; Armand B. Glassman; Moshe Talpaz; Hagop M Kantarjian
Translocation t(17;18)(q10;q10): a new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia.
Cancer 2001;91(9):1704-8.
2000: Jose Rodriguez; Jorge Romaguera; J Manning; Nelson G Ordonez; Chul Ha; Farhad Ravandi; Fernando Cabanillas
Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases.
Leukemia & lymphoma 2000;39(1-2):139-44.
1999: Farhad Ravandi; Zeev Estrov; Razelle Kurzrock; J B Breitmeyer; B J Maschek; Moshe Talpaz
A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3990-8.
1999: Farhad Ravandi; Jorge Cortes; Maher Albitar; Ralph B Arlinghaus; J Qiang Guo; Moshe Talpaz; Hagop M Kantarjian
Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance.
British journal of haematology 1999;107(3):581-6.